The ceramide/sphingosine-1-phosphate (S1P) rheostat has been hypothesized to play a critical role in regulating tumor cell fate, with elevated levels of ceramide inducing death and elevated levels of S1P leading to survival and proliferation.
Introduction
The mechanisms and effects of the interconversion of sphingolipids have been the subject of a growing body of scientific investigation (reviewed in (1) (2) (3) (4) (5) (6) (7) ). In the sphingolipid metabolic pathway, ceramide is produced by the hydrolysis of sphingomyelin in response to several growth stimulatory and/or inflammatory signals, and the accumulation of ceramide induces apoptosis in tumor cells without disrupting quiescent normal cells (8) (9) (10) (11) . In turn, ceramide can be hydrolyzed by the action of ceramidase enzymes to produce sphingosine, which is phosphorylated by sphingosine kinases (SK1 and SK2) to produce sphingosine-1-phosphate. It has been hypothesized that a critical balance, i.e. a ceramide / S1P rheostat, exists that determines the fate of the cell (12) (13) . When cells are exposed to mitogens, a rapid increase in intracellular levels of S1P is induced along with a depletion of ceramide.
These conditions support cell survival and proliferation. In contrast, an accumulation of ceramide occurs with the activation of sphingomyelinase in the absence of ceramidase and/or SK activity resulting in an apoptotic response (reviewed in (14) ).
In addition, it has been demonstrated that tumor cells can escape apoptosis by rapidly removing ceramide with ceramidases (reviewed in (15) ). This makes the ceramidases interesting targets for anticancer drug development because inhibiting their activity leads to an accumulation of ceramide and tumor cell death (16) (17) (18) (19) (20) . In addition, ceramide has been reported to enhance apoptosis in response to paclitaxel (21) , etoposide (10) and gemcitabine (22) (23) . Therefore, inhibition of ceramidase activity could also increase tumor chemosensitivity. It has been demonstrated that ceramidases are over-expressed in several forms of cancer including prostate, head and neck, and melanoma (24) (25) (26) (27) (28) . In addition, over-expression of ceramidases has been shown to confer tumor cell resistance to tumor necrosis factor and radiation (29) (30) (31) . Conversely, exposure to exogenous ceramides or sphingomyelinase, which generates ceramide, have been shown to induce apoptosis in pancreatic cancer and leukemia cell lines (32) (33) .
Overall, these findings support ceramidases as viable targets for the development of novel anticancer agents. In spite of the high level of basic interest in sphingolipid-mediated signaling, the pharmacology of ceramidase inhibition remains poorly characterized (34) . A few compounds including N-oleoylethanolamine, B13, De-MAPP and D-NMAPPD have been characterized as inhibitors of ceramidase activity (18-19, 29, 35-37) , and treatment of cancer cells with these inhibitors induces the accumulation of ceramide and promotes apoptosis in colon, prostate, glioma, and melanoma cell lines (18-19, 29, 37) . However, these compounds have significant pharmaceutical shortcomings that will likely hinder their development as clinically viable therapeutics. Most importantly, the current ceramidase inhibitors are typically ceramide analogs containing long-chain alkyl moieties. Highly hydrophobic compounds such as these tend to have poor pharmacologic properties due to binding with albumin, resulting in poor bioavailability. Thus, there is a need to identify "drug-like" small molecule inhibitors of ceramidases that can be developed into anticancer agents.
In this study, we sought to identify novel small molecule inhibitors of ceramidase activity with favorable pharmacologic properties that can be further developed into anticancer therapeutics. We herein demonstrate that our newly identified compounds inhibit the hydrolysis of an exogenous ceramidase substrate, and induce the accumulation of ceramide while decreasing intracellular levels of sphingosine and S1P.
Additionally, these new ceramidase inhibitors are antiproliferative and proapoptotic, and have in vivo antitumor activity. was cooled and poured slowly, with stirring, into an ice-cold solution of 40 ml of water.
Materials and Methods

Materials
The resulting suspension was allowed to stand in an ice bath until the gummy precipitate had hardened, after which the crude product was collected, washed with water, and recrystallized from aqueous ethanol to give 1.82 g of 3-acetyl-4-phenyl-1H-quinolin-2-one (3, 70% yield) as off-white needles, with a melting point of 256-258°C. 2) NaOH powder (12 mmol) was added to a 50 ml round-bottom flask containing a 20 ml EtOH plus 10 ml CH 2 Cl 2 solution of 3 and 4-methoxybenzaldehyde (4, 4 mmol) under N 2 and stirred at 25 °C overnight. The reaction mixture was acidified to pH 3, washed three times with water (3 x 10 ml), and filtered to give the crude product 3-[3- Cellular ceramidase assay. Ceramidase activity in human ovarian adenocarcinoma (SKOV3) cells over 24 hr was measured using a previously described fluorogenic ceramidase substrate (38) according to our previously published protocol (39) . Briefly, SKOV3 cells were grown to near confluence in 96-well plates, and then incubated with
yl)palmitamide (ceramidase substrate) for 24 hr at 37 °C. After incubation, the ceramidase cleavage product was converted to umbelliferone by adding 100 µl of 100%
MeOH, 100 µl of NaIO4 (10 mg/ml in 100 mM phosphate buffer pH 8.0) and 50 µl of BSA (2 mg/ml in 100 mM phosphate buffer pH 8.0) and incubating overnight at 37 °C.
The following day the samples were analyzed using a SpectraMax M5 platereader Ceranib-2 alone or in combination with paclitaxel for 72 hr, followed by cell quantification using the sulforhodamine assay (40) in MeOH). The samples were fractionated by reverse-phase HPLC on a Supelco Discovery C18 column (20 × 2.1 mm) using a linear gradient beginning with 30% Solvent A and 70% Solvent B (5% acetonitrile and 0.1% formic acid in water) and ending with 100% Solvent B over 9 min at a flow rate of 0.4 ml/min. Ceranib-2 eluted at approximately 10.2 min, and was quantified by measuring its absorbance at 341 nm using a calibration curve of pure Ceranib-2.
Results
Screen for inhibitors of human ceramidase activity. A ceramide analog that generates a fluorescent product following cleavage by ceramidase (38) was used to screen a ChemBridge DIVERset library consisting of approximately 50,000 drug-like compounds. SKOV3 cells were exposed to pools of 10 compounds (each at a final concentration of 30 µM) and incubated with the fluorogenic ceramide overnight.
Ceramidase activity was measured as the increase in fluorescence as previously described (39) . This assay was found to have an average Z'-factor of 0.71, indicating that it is suitable for screening for ceramidase inhibitors. Compound pools that inhibited ceramidase activity were deconvoluted to identify individual active compounds, which were defined as those that reduced ceramidase activity by at least 75% at 100 µM. This criterion was satisfied by only 0.03% of the screened compounds, and the 3-phenylacryloyl-4-phenyl-1H-quinolin-2-one scaffold was identified in multiple screening hr. Subsequently, increased fluorescence produced by the hydrolysis of a fluorogenic ceramidase substrate by cellular ceramidase enzymes was measured. As shown in Figure 2A , both compounds produce a dose-dependent decrease in ceramidase activity, with 50% inhibition at 55 and 28 µM for Cerenib-1 and Ceranib-2, respectively.
To ensure that the decreases in ceramidase activity were not caused by toxicity to the cells in this timeframe, SKOV3 cells in identical culture conditions were treated with Ceranib-1 or Ceranib-2 for 24 hr and the metabolic viability of the cells was determined using the MTS assay. As shown in Figure 2B , neither compound caused significant cytotoxicity at concentrations up to at least those used in the ceramidase assay, indicating that the reduction in activity observed is not due to cell death. To compare the potency of our new compounds to previously described ceramidase inhibitors, we treated SKOV3 cells with DMAPP or N-oleoylethanolamine. DMAPP had no affect on ceramidase activity or cell survival up to at least 300 µM, whereas Noleoylethanolamine had no affect on ceramidase activity in this assay but did induce cell death with an IC 50 of 50 ± 16 µM. Therefore, the Ceranibs are considerably more potent than these lipid analogs for inhibiting ceramidase activity in an intact cell. 
To determine if the compounds are able to inhibit the hydrolysis of endogenous ceramides, SKOV3 cells at near-confluence were treated with Ceranib-1 or Ceranib-2 for 24 hr and the levels of intracellular sphingolipid and dihydrosphingolipid species were quantified by HPLC-mass spectrometry. As indicated in Figure 3A , treatment with 12.5 µM Ceranib-1 induced an accumulation of ceramide species including C 14 , C 24 , C 26 and C 26:1 , with an overall increase of approximately 32% in total ceramide levels compared with vehicle-treated cells. In addition, Ceranib-1 induced a dose-dependent decrease in the intracellular levels of both sphingosine and S1P to 10 and 34% of vehicle-treated cells, respectively. Concerning the dihydrosphingosine species, Figure   3C demonstrates that Ceranib-1 had no affect on the levels of these lipids until a concentration of 50 µM, at which point the levels of dhC 16 Like Ceranib-1, Ceranib-2 caused a dose-dependent decrease in the intracellular levels of sphingosine and S1P to 16 and 30% of vehicle-treated cells, respectively. Also, as seen in Figure 3D , Ceranib-2 caused an increase in the levels of dhC 16 -Cer at every concentration tested, reaching a peak of approximately 800% of that found in vehicletreated cells at 50 µM Ceranib-2. In contrast, this compound did not cause a large elevation in the levels of dhS1P, and induced a decrease of intracellular dhSph.
Overall, these data suggest that the compounds prevent the hydrolysis of endogenous ceramide species and reduce intracellular sphingosine and S1P. Figure 6A , the average normalized size of tumors in each treatment group increased over time. However, by Day 11 both Ceranib-2-treated groups had significantly lower tumor volumes than did the vehicle-treated controls. By Day 21, the average normalized tumor volumes for the control, 20 mg/kg and 50 mg/kg Ceranib-2 groups were 1400 ± 370, 940 ± 290, and 710 ± 170%, respectively. Administration of Ceranib-2 did not affect the total body weight of the animals (insert in Figure 6A) . Also, blood samples from three representative mice of each group were assessed for blood chemistry and complete blood cell counts, and all groups were statistically equivalent (data not shown). Finally, in preliminary pharmacokinetic evaluations (Figure 6B its circulating levels, reaching a peak plasma concentration of approximately 40 µM at the 2 hr time point. This concentration of Ceranib-2 is well-above that required to inhibit cell proliferation; however, the compound appears to be cleared with a half-life of less than 2 hr.
As indicated in
Discussion
To identify inhibitors of ceramidase activity with more favorable "drug-like" properties than existing compounds, a high-throughput screen was developed in SKOV3 cells using a previously described fluorogenic ceramidase assay (39) , and approximately 50,000 compounds from the ChemBridge DIVERset Library were screened. Ceranib-1 emerged from the screen as a lead compound, and several analogs were synthesized to begin the assessment of structure-activity relationships. not simply due to cell death. In contrast, DMAPP did not decrease cellular ceramidase activity nor cell viability at up to at least 300 µM. While Noleoylethanolamine did decrease cellular viability with an IC 50 of 50 µM, it did not affect cellular ceramidase activity below 300 µM, suggesting that it can induce cell death by a mechanism other than ceramidase inhibition. This is not surprising since N-oleoylethanolamine is a highly hydrophobic analog of ceramide that may have a variety of membrane-disruptive effects. In any case, the data demonstrate that our experimental compounds Ceranib-1 and -2 are more potent inhibitors of ceramidase activity than the commonly used ceramidase inhibitors DMAPP and Noleoylethanolamine. Furthermore, these compounds meet all of the Lipinski "Rule of Five" requirements for a drug-like compound, making them more amenable to further development.
To determine if the compounds inhibit the activity of the ceramidase enzymes toward endogenous ceramide species, SKOV3 cells were treated with the compounds under similar conditions to those in the high-throughput screen, and levels of intracellular sphingolipid and dihydrosphingolipid species were determined. Both compounds caused an accumulation of various ceramides and decreases in sphingosine and S1P. These data suggest that the compounds are inhibiting the activity of one or more ceramidase enzymes, causing an accumulation of ceramide species and decreasing the levels of sphingosine, the product of ceramidase activity.
While both compounds demonstrate a roughly similar ability to decrease the intracellular levels of sphingosine and S1P, Ceranib-2 caused a greater accumulation of total ceramides than did Ceranib-1. This observation supports the 
dose-response data indicating that Ceranib-2 is a more potent inhibitor of ceramidase activity than is Ceranib-1.
To determine the effect of these compounds on replicating cancer cells, SKOV3 cells in exponential growth were treated with the compounds and incubated for 72 hr. Both compounds produced a substantial decrease in the number of cells; however, Ceranib-2 was approximately 5 times more potent than Ceranib-1 with IC 50 values of 0.73 and 3.92 µM, respectively. There are two potential explanations for this difference in potency compared with the cell-based ceramidase activity assay.
First, the ceramide/S1P rheostat model dictates that as the balance shifts in the direction of greater total ceramides and lower S1P cells undergo apoptosis. Thus, because lower concentrations of Ceranib-2 cause a greater accumulation of total ceramides than Ceranib-1, Ceranib-2 causes a shift in the rheostat at lower concentrations leading to cell death. Second, Ceranib-1 greatly increases the levels of intracellular dhS1P, whereas Ceranib-2 does not. DhS1P is known to activate the ERK signaling pathway, which stimulates survival and proliferation (41) . It should also be noted that both compounds induce an accumulation of the anti-apoptotic species dhC 16 -Cer, which has been shown to inhibit ceramide channel formation in the mitochondria, decreasing permeabilization of the membrane, blocking apoptosis (42) . However, the increase in this ceramide species may simply be a survival response to the increase in pro-apoptotic ceramide species.
The fluorogenic ceramide analog used on our studies is a direct analog of saturated dhC 16 -Cer. Therefore, the cellular ceramidase assay is specifically measuring the activity of ceramidases that hydrolyze dhC 16 have shown that acid and neutral ceramidase have activity toward this substrate (43) (44) . In contrast, the alkaline ceramidases have not been reported to have activity toward this specific substrate (45) (46) . Therefore, it appears likely that the fluorogenic cellular assay is measuring the activity of acid and neutral ceramidases; however, we cannot conclude that our compounds only inhibit these two enzymes.
In addition, while the ceramidase isozymes demonstrate substrate specificity, there is considerable overlap among the isozymes. In particular, alkaline ceramidase 2 has a very broad range of substrate specificity, with activity toward ceramide species from C 2 to C 24 (47) . Therefore, we cannot attribute the observed accumulation of ceramide species to the inhibition of any one particular ceramidase enzyme. 
